Navigation Links
Ingredient in New MS Drug Linked to Serious Brain Disease
Date:4/24/2013

By Brenda Goodman
HealthDay Reporter

WEDNESDAY, April 24 (HealthDay News) -- The active ingredient in a drug that's expected to become a popular treatment for multiple sclerosis has been linked to four European cases of a rare but sometimes fatal brain disease called progressive multifocal leukoencephalopathy (PML).

The ingredient, dimethyl fumarate, is used in a drug called Fumaderm that was approved in Germany in 1994 to treat the skin condition psoriasis. It is also in a different but closely related medication called Tecfidera, which was just approved by the U.S. Food and Drug Administration in March for the treatment of multiple sclerosis (MS). It is known as a fumaric acid ester, which is commonly used as a food additive and has been used to treat psoriasis in Germany for 30 years.

According to reports published in the April 25 issue of the New England Journal of Medicine, however, four patients who were taking Fumaderm to treat their psoriasis developed PML.

In a letter responding to the reports, Biogen, the company that makes both drugs, said Tecfidera may be safer because it contains only dimethyl fumarate, while Fumaderm also contains three other fumaric acid esters.

The company also noted that none of the patients taking Tecfidera during clinical trials (then known as BG-12) developed PML. Since Tecfidera is a pill rather than an injection, and was effective and well-tolerated by patients in clinical trials, analysts have predicted it would soon become the top-selling multiple sclerosis treatment.

But the German doctor who treated one of the psoriasis patients who got PML thinks there is still cause for concern.

Dr. Jorg Schulz, a neurologist at Rheinisch-Westfaelische Technische Hochschule Aachen, a research university in Aachen, said the two drugs are virtually identical once they are broken down in the body.

"The problem is that the studies with BG-12 covered a two-year period, but no longer periods," Schulz said, and he believes it may take prolonged treatment with the drug for PML to surface.

"With the publication of our case, we wish to create awareness that treatment with any form of fumaric acid may bear the risk of developing PML," Schulz said.

PML is caused by the JC virus, which normally lies dormant in the body and causes no harm. About half of multiple sclerosis patients have antibodies to the JC virus in their blood, suggesting a current or former infection. When the immune system is depleted by illnesses like cancer or AIDS or suppressed by certain medications, the virus can flare and destroy nerve cells in the brain.

Ironically, PML is a lot like multiple sclerosis, but it progresses more rapidly as it causes weakness, paralysis, confusion, memory loss and loss of vision or speech. Quick treatment can stop the damage, although patients may be permanently disabled.

PML is rare, but it is so serious that Genentech pulled its psoriasis treatment Raptiva off the market in 2009 after reports of four cases in patients who were taking the biologic medication. Biologic drugs are medications derived from living organisms that are used to prevent certain diseases, including ones where the immune system malfunctions.

Another biologic, Tysabri, a treatment for multiple sclerosis and Crohn's disease, was shelved in 2005 for about a year after three patients involved in clinical trials of the drug developed PML. Tysabri returned to the market in 2006 with strict new safeguards in place. Before starting the drug, for example, patients must get an MRI of their brains. They also may get blood tests to check for antibodies to the JC virus. They also are monitored by doctors every three to six months while taking the medication, which is also made by Biogen.

No such precautions are currently recommended for Tecfidera, which has been hailed as a less toxic alternative to other treatments. Other multiple sclerosis drugs are known to cause flu-like symptoms, chest pain, and heart, liver and eye problems.

In clinical trials, the main side effects reported with Tecfidera were comparatively mild, and included facial flushing, stomach upset and low white blood cell counts.

"The main reason why our [psoriasis] patient developed PML after three years of treatment with Fumaderm is prolonged lymphocytopenia [low white blood cell counts]," Schulz said. "In both BG-12 trials published in the New England Journal of Medicine in 2012, 4 percent to 5 percent of patients developed this kind of severe lymphocytopenia and are in my view at risk to also develop PML."

Another expert noted another caveat.

About 3 percent of patients in the Tecfidera trials were taken off the medication when their white blood cell counts dropped too low, said Dr. Robert Fox, a staff neurologist at the Mellen Center for Multiple Sclerosis at the Cleveland Clinic in Ohio.

"The intensive monitoring of the clinical trial may have been what helped to prevent PML," said Fox, who was on the steering committee for one of the studies that tested the medication and who has been a paid consultant for Biogen.

Fox added that the PML case reports are "very important additions to our understanding of this class of therapy."

"Although we haven't seen any PML cases in patients treated with Tecfidera, I think there's good reason to apply the lessons learned here to Tecfidera," he said.

More information

For more on the risks and benefits of multiple sclerosis treatments, visit the National Multiple Sclerosis Society.

SOURCES: Jorg Schulz, M.D., neurologist, Rheinisch-Westfaelische Technische Hochschule Aachen, Aachen, Germany; Robert Fox, M.D., neurologist, Mellen Center for Multiple Sclerosis at the Cleveland Clinic, Ohio; April 25, 2013, New England Journal of Medicine


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Revitol Rosacea Now Comes with Anti-Inflammatory Ingredients to Remove Redness and Flushing
2. Wartrol Warts Relief Formula Now Comes With FDA Approved Ingredients For Fast Actions
3. Simply Eight Expands Distribution Of Its Simple Ingredient Foods
4. Advance in re-engineering photosynthesis to make drugs, compounds or ingredients
5. Capsiplex Fat Burner Formula with Red Pepper and Other Useful Ingredients for Quick Weight Loss
6. Some Kids Abusing Common Baking Ingredients
7. WeightWise Infographic Spotlights Twinkies Ingredients’ Non-Food Uses
8. EverydayVitamin.com Carries New Patented Satiereal® Saffron Extract Products: Proven Ingredient for Weight Loss
9. Pure Cocoa Powder, the Key Ingredient in Dark Chocolate and Found in Diabetes Support Supplements has been Clinically Proven to Reduce Cardiovascular Risk
10. Supplement of Red Wine Ingredient Wont Help Healthy Women: Study
11. Metabolic engineer synthesizes key breast milk ingredient, makes research possible
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Ingredient in New MS Drug Linked to Serious Brain Disease
(Date:3/23/2017)... ... ... March is National Kidney Month – the perfect time to pause and thank ... Every day, two kidneys filter about 120 to 150 quarts of blood. Put another ... regulating fluid levels and blood pressure, supporting bone health and promoting red blood cell ...
(Date:3/23/2017)... ... March 23, 2017 , ... The ... from the NCQA. The accreditation covers StayWell’s asthma, coronary artery disease, congestive heart ... granted to organizations that have excellent programs for the delivery and improvement of ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... program owned and organized by HMP Communications Holdings, LLC, today announced that ... within its nationwide network of wound centers interested in becoming Certified Wound Specialist ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... families and businesses of the greater Fort Collins area, has unveiled a collaboration ... ongoing community involvement program. Donations to this worthy cause may now be made ...
(Date:3/23/2017)... ... ... After raising more than $1.135 million ($1,479,231 AUD) from nearly 20,000 backers ... crowdfunding history, has established a U.S. Headquarters in New York City, FaceCradle USA, LLC, ... excited to be operating on U.S. shores, where most of our initial crowdfunding backers ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... YORK , March 23, 2017 ... (NASDAQ: MYL), Allergan PLC (NYSE: AGN), Horizon Pharma PLC (NASDAQ: ... These Generic Drugs stocks are part of the Healthcare sector, ... 22 nd , 2017, with the NYSE Health Care Index ... companies in the S&P 500 also were up nearly 0.1% ...
(Date:3/23/2017)... Global Colposcope Market by Manufacturers, Countries, Type and Application, Forecast ... in North America , Europe ... , Middle East and ... regions, type and application. ... Browse 190 Tables and Figures, 19 Major Company Profiles, spread ...
(Date:3/23/2017)... 23, 2017 During the ... Brussels , My UV Patch, La ... habits into life-saving ones, was awarded the Diamond ... in 2016, the "Nudging for Good" Award aims ... desirable for people to change behaviour and adopt ...
Breaking Medicine Technology: